World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00109161
Date of registration: 22/04/2005
Prospective Registration: No
Primary sponsor: PDL BioPharma, Inc.
Public title: Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Scientific title: A Phase II Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
Date of first enrolment: April 2005
Target sample size: 270
Recruitment status: Completed
URL:  http://clinicaltrials.gov/show/NCT00109161
Study type:  Interventional
Study design:  Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
Canada United States
Contacts
Name:     Ed Fox, M.D.
Address: 
Telephone:
Email:
Affiliation:  Central Texas Neurology
Name:     Sharon Lynch, M.D.
Address: 
Telephone:
Email:
Affiliation:  CLMC Neurology
Name:     Michael Kaufman, M.D.
Address: 
Telephone:
Email:
Affiliation:  MS Center/CMC
Name:     James R. Storey
Address: 
Telephone:
Email:
Affiliation:  Upstate Clinical Research
Name:     Theodore J. Phillips, M.D.
Address: 
Telephone:
Email:
Affiliation:  The MS Center at Texas Neurology
Name:     Neil Lava, M.D.
Address: 
Telephone:
Email:
Affiliation:  Albany Medical College
Name:     Christopher Bever, M.D
Address: 
Telephone:
Email:
Affiliation:  Maryland Center for MS
Name:     Yves Lapierrre, M.D.
Address: 
Telephone:
Email:
Affiliation:  Montreal Neurological Institute
Name:     Florian P. Thomas, M.D.
Address: 
Telephone:
Email:
Affiliation:  St. Louis University Hospital
Name:     Jeffrey English, M.D.
Address: 
Telephone:
Email:
Affiliation:  The Multiple Sclerosis Center of Atlanta
Name:     Clyde Markowitz, M.D.
Address: 
Telephone:
Email:
Affiliation:  University of Pennsylvania
Name:     MaryAnn Picone, M.D.
Address: 
Telephone:
Email:
Affiliation:  Gimble MS Center
Name:     Maria Melanson, M.D.
Address: 
Telephone:
Email:
Affiliation:  Health Sciences Center
Name:     Marcelo Kremenchutzky, M.D.
Address: 
Telephone:
Email:
Affiliation:  London Health Sciences Centre
Name:     Jayne Martin, M.D.
Address: 
Telephone:
Email:
Affiliation:  Michigan State University
Name:     Kasper Lloyd, M.D.
Address: 
Telephone:
Email:
Affiliation:  MS Center at Dartmouth
Name:     William Honeycutt, M.D.
Address: 
Telephone:
Email:
Affiliation:  Neurology Associates, P.A.
Name:     Steven Pugh, M.D.
Address: 
Telephone:
Email:
Affiliation:  Rockwood Clinic, PS
Name:     Andrew Goodman, M.D.
Address: 
Telephone:
Email:
Affiliation:  University of Rochester
Name:     Francois Jacques, M.D.
Address: 
Telephone:
Email:
Affiliation:  Clinique SEP/NM
Name:     Daniel Wynn, M.D.
Address: 
Telephone:
Email:
Affiliation:  Consultants in Neurology
Name:     Alireza Minagar, M.D.
Address: 
Telephone:
Email:
Affiliation:  Louisiana State University Health Sciences Center
Name:     S. Mitchell Freedman, M.D.
Address: 
Telephone:
Email:
Affiliation:  Raleigh Neurology Associates
Name:     Malcolm Gottesman, M.D.
Address: 
Telephone:
Email:
Affiliation:  Winthrop University Hospital
Name:     Herman Sullivan, M.D.
Address: 
Telephone:
Email:
Affiliation:  Michigan Medical P.C. Neurology
Name:     Jeffery Dunn, M.D.
Address: 
Telephone:
Email:
Affiliation:  MS Hub Medical Group
Name:     Joanna Cooper
Address: 
Telephone:
Email:
Affiliation:  Sutter East Bay Medical Foundation
Name:     Omar Khan, M.D.
Address: 
Telephone:
Email:
Affiliation:  Wayne State University MS Center
Name:     Richard Dickson, M.D.
Address: 
Telephone:
Email:
Affiliation:  Wenatchee Valley Medical Center
Name:     Michael Yeung, M.D.
Address: 
Telephone:
Email:
Affiliation:  Foothills Medical Centre
Name:     Jonathan L. Carter, M.D.
Address: 
Telephone:
Email:
Affiliation:  Mayo Clinic
Name:     John W. Rose, M.D.
Address: 
Telephone:
Email:
Affiliation:  University of Utah CAMT
Name:     Joseph Herbert, M.D.
Address: 
Telephone:
Email:
Affiliation:  Hospital for Joint Diseases, MS Care Center
Name:     Timothy Vollmer, M.D.
Address: 
Telephone:
Email:
Affiliation:  St. Joseph's Hospital and Medical Center, Phoenix
Name:     Gregg G. Blevins, M.D.
Address: 
Telephone:
Email:
Affiliation:  University of Alberta
Name:     Istvan Pirko, M.D.
Address: 
Telephone:
Email:
Affiliation:  University of Cincinnati
Key inclusion & exclusion criteria

Inclusion Criteria:

- Male or female age 18 to 55 years, inclusive.

- Diagnosis of MS by McDonald criteria.

- EDSS <7.0.

- On stable IFN-beta regimen for at least 6 months.

- The occurrence of either of the following within 9 months prior to screening: =1
MS relapse OR A qualifying MRI, defined as an MRI that showed at least one confirmed
Gd-CEL of the brain or spinal cord, was performed independently of the study while
the patient was on a stable IFN-beta regimen, and is deemed acceptable by the central
reader.

- For females, women of non-childbearing potential or women of childbearing potential
who provide a negative serum pregnancy test at screen and within 24 hours of first
dose of study drug, and who agree to use effective contraception during the Treatment
and Follow-up periods of the study.

- Willing and able to comply with the protocol, provision of informed consent in
accordance with institutional and regulatory guidelines, and, for US sites only,
authorization to use protected health information.

Exclusion Criteria:

- Pregnant or breast-feeding woman.

- Non-ambulatory patient.

- Clinically significant abnormality on screening ECG.

- Malignancy within the past 5 years, except for adequately treated non-melanoma skin
carcinoma or in situ carcinoma of the cervix.

- History of HIV infection, positive serology for HBV (hepatitis B virus) or HCV
(hepatitis C virus).

- Varicella (VZV) or herpes zoster virus infection, or any severe viral infection,
within 6 weeks before screening or exposure to VZV within 21 days of screening.

- Abnormal hematology, as defined by the following laboratory values: *Hemoglobin =8.5
g/dL, *Lymphocytes =1.0 x 10^9/L, *Platelets =100 x 10^9/L, *Neutrophils =1.5 x
10^9/L.

- Significant organ dysfunction, including but not limited to cardiac, renal, liver,
non-MS related CNS, pulmonary, vascular, gastrointestinal, endocrine, or metabolic
dysfunction, or other disease or condition, which in the opinion of the PI (principal
investigator) would make the patient an unsuitable candidate for the study.
Guidelines for levels of unacceptable dysfunction include: *creatinine =1.6 mg/dL;
*AST and ALT =2.5 times upper limit of normal (ULN); *alkaline phosphatase =2.5 times
ULN; *history of myocardial infarction, congestive heart failure, or arrhythmias
within 6 months prior to randomization.

- Use of any of the following: *Any of the following types of live virus vaccine from 4
weeks before randomization: measles/mumps/rubella vaccine, varicella zoster virus
vaccine, oral polio vaccine, and nasal influenza vaccine. Use of these vaccines,
however, by household contacts does not affect the eligibility of patients to enroll
or continue in the study; *Systemic corticosteroids, adrenocorticotropic hormone, or
plasma exchange within 4 weeks before the baseline MRI scan (no more than 72 hours
before Day 0); *Azathioprine, mycophenolate mofetil, methotrexate, glatiramer
acetate, or intravenous immune globulin within 6 months before randomization; *An
immunomodulatory agent within 6 months before randomization, except for
interferon-beta products required per protocol; *An investigational agent within 6
months before randomization unless this agent is non-immunomodulatory and the medical
monitor or steering committee rules that its use is acceptable on the theoretical
basis of a lapse of at least 5 serum half-lives since administration of the last
possible dose; *A monoclonal antibody (eg, Rituxan®/ Rituximab) within 6 months
before randomization; *Daclizumab at any time prior to randomization; *Cladribine,
mitoxantrone, cyclophosphamide, CamPath® (alemtuzumab), natalizumab
(TYSABRI®/Antegren) or other drugs targeting alpha 4 integrin, total lymphoid
irradiation, or bone marrow transplant at any time

- Patients for whom MRI is contraindicated, ie, have pacemakers or other
contraindicated implanted metal devices, are allergic to gadolinium, or have
claustrophobia that cannot be medically managed.

- Primary progressive MS.

- Clinically unstable for 30 days before randomization (Patients who experienced a
relapse, with or without steroid treatment, during the screening period may be
re-screened after 30 days.)

- Elective surgery performed from 2 weeks prior to randomization or scheduled through
Week 44

- Infection (viral, fungal, bacterial) requiring hospitalization or IV antibiotics
within 8 weeks before randomization.



Age minimum: 18 Years
Age maximum: 55 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Multiple Sclerosis
Intervention(s)
Drug: Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)
Primary Outcome(s)
Number of new or enlarged gadolinium contrast enhancing lesions (Gd-CELs) on monthly brain MRIs collected between Weeks 8 to 24 in daclizumab- vs. placebo-treated patients
Secondary Outcome(s)
Clinical improvement
Pharmacokinetics
Immunogenicity
Secondary ID(s)
DAC-1012
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey